Recent changes in the management of community acquired pneumonia in adults

BMJ

Volumn 336, Issue 7658, 2008, Pages 1429-1433

  Durrington, Hannah J ^a   Summers, Charlotte ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HUMAN; INCIDENCE; LEGIONELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; LONG-TERM CARE; METHICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 46749147713     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a285     Document Type: Review

References (29)

1. Osler W. The principles and practice of medicine. 4th ed. New York: D Appleton, 1901.
2. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(p- aminobenzenesulphonamido) pyridine. Lancet 1938;2:14-9.
3. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community acquired pneumonia? Diagnosing pneumonia by history and clinical examination? JAMA 1997;278:1440-5.
4. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;1:671-4.
5. British Thoracic Society Standards of Care Committee in collaboration with and endorsed by the Royal College of Physicians of London, Royal College of General Practitioners, British Geriatrics Society, British Lung Foundation, British Infection Society, British Society for Antimicrobial Chemotherapy, and Public Health Laboratory Service. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56:1-64.
6. Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301.
7. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001.
8. Arnold FW, Summersgill JT, LaJoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93.
9. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingolg A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63.
10. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007;3:e168.
11. Health Protection Agency. Antimicrobial resistance in England, Wales and Northern Ireland, 2006. 2007. www.hpa.org.uk/web/HPAwebFile/HPAweb_C/ 1204100435389.
12. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12:894-9.
13. Center for Disease Control. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325-9.
14. Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what's new? Thorax 2004;59:364-6.
15. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
16. Mills DG, Oehley MR, Arrol B. Effectiveness of beta-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456-62.
17. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44.
18. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-5.
19. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9.
20. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007;120:783-90.
21. Moussaoui RE, de Borgie CAJM, van den Broek P, Hustinx WN, Bresser P, van den Berk GEL, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355-61.
22. Oosterheert JJ, Bonten MJM, Schneider MME, Buskens E, Lammers JWJ, Hustinx WMN, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;333:1193-7.
23. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community acquired pneumonia. Results from the pneumonia patient outcomes research team cohort study. Arch Intern Med 1997;157:36-44.
24. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
25. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997;336:243-50.
26. Man SY, Lee N, Ip M, Antonio GE, Chau SSL, Mak P, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007;62:348-53.
27. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, Capnetz Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260:93-101.
28. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006;61:419-24.
29. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky SD, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-92.